Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Stock Information for Axogen Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Axogen Inc.

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix(TM)
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
Axogen Announces Promotions on Research and Development Team

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.